← boardnext 2026-08-21next 2026-09-01next 2026-10-01next 2026-12-14next 2027-01-14next 2027-01-25next 2027-05-16next 2027-08-25next 2027-08-27next 2027-11-07next 2028-02-29next 2028-06-06next 2028-06-30next 2028-10-10
NONOF
Novo Nordisk A/Sdistress 2/10 · well-funded / low risk$48.49-3%today-31% from 52w high
Metabolic / Obesity 2
Lead: Obesity · est. market ~$15B (approx, global)
Revenue
$96823M
Liquidity
$23867M
Runway
—
Shares 1y
—
Price & events
-19.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.6%
1D
-3.3%
1W
+5.2%
1M
+24.4%
3M
-19.3%
6M
-24.6%
1Y
-60.9%
2Y
+19.9%
5Y
+50.4%
All
Overview
- Volume
- 2.80K
- 52 Week Range
- $35.03 – $70.07
- Float Shares
- 3.18B
- % Held by Insiders
- 5.28%
- % Held by Institutions
- 33.52%
- RVOL
- 0.13x
- Beta
- 0.36
Pipeline stages · 16 programs
Cagrilintide, Semaglutide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
NNC0519-0130, Semaglutide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Ziltivekimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
NNC0662-0419, Semaglutide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
UBT251, Semaglutide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Insulin icodec, Insulin glargine, Insulin aspart
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CDR132L
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Cagrisema, Semaglutide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Etavopivat A, Etavopivat B, Etavopivat C
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Semaglutide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Show all 16 programs · 6 more ▾
NNC6019-0001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
NNC0487-0111
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Mim8
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Zenagamtide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
NNC0471-0119 H, Insulin aspart
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
NNC0491-6075
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 45 trials · 42 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-21 Estimated 50% readout ~2026-10-05 final ~2027-01-31 | Phase 2 | CagriSema (Cagrilintide B and Semaglutide I) | Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy | — | active not recruiting |
| 2026-09-01 Estimated 50% readout ~2026-10-16 | Phase 2 | NNC0519-0130, Semaglutide | Chronic Kidney Disease | — | recruiting |
| 2026-10-01 Estimated 50% readout ~2026-12-15 | Phase 3 | Ziltivekimab | Heart Failure, Systemic Inflammation | — | recruiting |
| 2026-12-14 Estimated 50% readout ~2027-02-27 | Phase 3 | Ziltivekimab | Cardiovascular Risk, Acute Myocardial Infarction (AMI) | — | recruiting |
| 2026-12-14 Estimated 50% readout ~2027-01-28 | Phase 2 | NNC0662-0419 | Overweight, Obesity | — | active not recruiting |
Show all 45 trials · 40 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-01-14 Estimated 50% readout ~2027-02-28 | Phase 2 | UBT251 | Overweight, Obesity | — | recruiting |
| 2027-01-25 Estimated 50% readout ~2027-04-10 | Phase 3 | Insulin icodec, Insulin glargine, Insulin aspart | Diabetes Mellitus, Type 1 | — | recruiting |
| 2027-03-01 Estimated 50% readout ~2027-05-15 | Phase 3 | CagriSema (Cagrilintide B and Semaglutide I) | Obesity | — | active not recruiting |
| 2027-05-11 Estimated 50% readout ~2027-07-25 | Phase 3 | Cagrilintide | Obesity, Overweight | — | active not recruiting |
| 2027-05-12 Estimated 50% readout ~2027-07-26 | Phase 3 | Cagrilintide | Overweight, Obesity, Type 2 Diabetes | — | active not recruiting |
| 2027-05-16 Estimated 50% readout ~2027-06-30 | Phase 2 | CDR132L | Heart Failure | — | recruiting |
| 2027-05-16 Estimated 50% readout ~2027-06-30 | Phase 2 | CDR132L | Heart Failure | — | recruiting |
| 2027-07-02 Estimated 50% readout ~2027-09-15 | Phase 3 | Ziltivekimab | Heart Failure | — | recruiting |
| 2027-07-12 Estimated 50% readout ~2027-08-26 | Phase 2 | NNC0662-0419, Semaglutide | Obesity | — | not yet recruiting |
| 2027-08-25 Estimated 50% readout ~2027-10-09 | Phase 2 | CagriSema | Diabetes Mellitus, Type 2 | — | not yet recruiting |
| 2027-08-27 Estimated 50% readout ~2027-11-10 | Phase 3 | Etavopivat | Sickle Cell Disease | — | recruiting |
| 2027-09-01 Estimated 50% readout ~2027-11-15 | Phase 3 | Cagrilintide, Semaglutide | Cardiovascular Disease | — | active not recruiting |
| 2027-09-03 Estimated 50% readout ~2027-10-18 | Phase 2 | NNC0662-0419, Semaglutide | Diabetes Mellitus, Type 2 | — | recruiting |
| 2027-10-04 Estimated 50% readout ~2027-11-18 | Phase 2 | UBT251, Semaglutide | Diabetes Mellitus, Type 2 | — | not yet recruiting |
| 2027-11-07 Estimated 50% readout ~2028-01-21 | Phase 3 | Semaglutide | Diabetes Mellitus, Type 2 | — | active not recruiting |
| 2027-11-29 Estimated 50% readout ~2028-02-12 | Phase 3 | Cagrisema | Overweight, Obesity | — | not yet recruiting |
| 2028-02-23 Estimated 50% readout ~2028-05-08 | Phase 3 | Cagrisema, Semaglutide | Obesity, Type 2 Diabetes | — | recruiting |
| 2028-02-29 Estimated 50% readout ~2028-04-14 | Phase 2 | NNC6019-0001 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | — | active not recruiting |
| 2028-06-06 Estimated 50% readout ~2028-08-20 | Phase 3 | NNC0487-0111 | Obesity | — | recruiting |
| 2028-06-26 Estimated 50% readout ~2028-09-09 | Phase 3 | NNC0487-0111 | Obesity, Overweight, Obstructive Sleep Apnoea | — | recruiting |
| 2028-06-30 Estimated 50% readout ~2028-09-13 | Phase 3 | Mim8 | Haemophilia A, Haemophilia A With Inhibitors | — | recruiting |
| 2028-07-12 Estimated 50% readout ~2028-09-25 | Phase 3 | NNC0487-0111 | Obesity, Overweight, Obstructive Sleep Apnoea | — | recruiting |
| 2028-08-07 Estimated 50% readout ~2028-10-21 | Phase 3 | NNC0487-0111 | Diabetes Mellitus, Overweight, Obesity | — | recruiting |
| 2028-08-14 Estimated 50% readout ~2028-10-28 | Phase 3 | NNC0487-0111 | Obesity, Knee Osteoarthritis (OA) | — | recruiting |
| 2028-08-14 Estimated 50% readout ~2028-10-28 | Phase 3 | NNC0487-0111 | Obesity, Overweight, Osteoarthritis, Knee | — | recruiting |
| 2028-08-28 Estimated 50% readout ~2028-11-11 | Phase 3 | Cagrilintide, Semaglutide | Obesity | — | active not recruiting |
| 2028-10-10 Estimated 50% readout ~2028-12-24 | Phase 3 | Zenagamtide, Semaglutide | Overweight, Obesity | — | not yet recruiting |
| 2028-11-14 Estimated 50% readout ~2029-01-28 | Phase 3 | Ziltivekimab | Myocardial Infarction | — | recruiting |
| 2028-12-12 Estimated 50% readout ~2029-02-25 | Phase 3 | NNC0487-0111, Semaglutide | Obesity, Overweight, Diabetes Mellitus, Type 2 | — | not yet recruiting |
| 2029-01-11 Estimated 50% readout ~2029-03-27 | Phase 3 | Zenagamtide | Obesity, Overweight | — | not yet recruiting |
| 2029-04-25 Estimated 50% readout ~2029-07-09 | Phase 3 | Semaglutide | Non-alcoholic Steatohepatitis | — | active not recruiting |
| 2029-06-26 Estimated 50% readout ~2029-09-09 | Phase 3 | NNC0487-0111 | Obesity | — | recruiting |
| 2029-06-29 Estimated 50% readout ~2029-09-12 | Phase 3 | NNC6019-0001 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | — | recruiting |
| 2029-07-23 Estimated 50% readout ~2029-10-06 | Phase 3 | NNC0487-0111 | Obesity, Heart Failure | — | recruiting |
| 2029-09-07 Estimated 50% readout ~2029-11-21 | Phase 3 | CagriSema (Cagrilintide B and Semaglutide I) | Diabetes Mellitus, Type 2 | — | not yet recruiting |
| 2030-03-20 Estimated 50% readout ~2030-06-03 | Phase 3 | Cagrilintide, Semaglutide | Overweight, Obesity | — | recruiting |
| 2030-12-30 Estimated 50% readout ~2031-03-15 | Phase 3 | Etavopivat A, Etavopivat B, Etavopivat C | Sickle Cell Disease, Thalassemia | — | recruiting |
| 2025-07-16 | Phase 1 | NNC0471-0119 H, Insulin aspart | Diabetes Mellitus, Type 1 | 43 | completed |
| 2025-05-08 | Phase 3 | Insulin icodec, Insulin glargine | Diabetes, Type 2 | 429 | completed |
| 2025-03-14 | Phase 1 | NNC0491-6075 | Healthy Volunteers, Dyslipidaemia | 106 | completed |
Catalyst news & presentations · 1
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Obesity
- LLYELI LILLY & Co$1094.4B · D3
- AMGNAMGEN INC$195.4B · D3
- GPCRStructure Therapeutics Inc.$11.2B · D4
- RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
- MBXMBX Biosciences, Inc.$2.8B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- GUTSFRACTYL HEALTH, INC.$123M · D9
- VANIVivani Medical, Inc.$118M · D7
- MTVAMetaVia Inc.$8M · D7
Recent news
- 2026-07-22Here's Why Novo Nordisk (NVO) Fell More Than Broader Market - Yahoo Finance
- 2026-07-21World in Brief: Burnham promises first tax cuts; Novo Nordisk sues Eli Lilly - The Economist
- 2026-07-21Africa’s most developed pharmaceutical market reviews 12 Ozempic generics as drugmakers target Novo Nordisk’s dominance - Business Insider Africa
- 2026-07-21Novo Nordisk Sues Eli Lilly for False Advertising: Weight-Loss Drug Data War Escalates, GLP-1 $100 Billion Market Fight Heats Up - TradingKey
- 2026-07-21Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising - Benzinga
- 2026-07-21Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing - The Motley Fool
- 2026-07-21Novo Nordisk Shares Down 2% After Co Sues Lil - Moomoo
- 2026-07-21Novo Nordisk stock trades near record levels as Ozempic and Wegovy fuel double digit growth - Ad-hoc-news.de
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.